Baidu
map

通知!20个药被重点监控

2019-04-01 遥望 赛柏蓝

近日,赣州市第五人民医院发布重点药品监控目录,前列地尔注射液、醒脑静注射液等20个药品在列。

近日,赣州市第五人民医院发布重点药品监控目录,前列地尔注射液、醒脑静注射液等20个药品在列。

▍大三甲重点监控20个药

据赣州市第五人民医院的通知:

根据赣州市卫健委《赣州市卫生健康委关于调整2019年第一批重点药品监控目录的通知》文件的相关要求,结合我院2018年7—12药品实际使用情况,决定对我院重点药品监控目录进行动态调整。

将恩替卡韦分散片(润众)[基]、异甘草酸镁注射液(天晴甘美)等20个药品纳入《2019年第一批重点监控药品目录》中。

经查询赣州市第五人民医院官网发现,赣州市第五人民医院是一家三级甲等公立医院。

2008年11月挂牌运行,同时挂牌赣南医学院附属赣州市第五人民医院、赣州市肝病医院、赣州市肺科医院、赣州市传染病医院。

▍近10个辅助用药被监控

有业内人士向赛柏蓝指出,赣州市第五人民医院的2019年第一批重点监控药品目录有近10个辅助用药,和几个抗生素,可见,这一批重点监控直指辅助用药。

此外,不少抗生素由于用量大,而且存在滥用也经常被重点监控。

可以说,只要是使用量大、金额高、用药不适宜的药品均有可能被重点监控。

重点监控药品制度,从省级、市级,到公立医院,是层层下沉,逐步扩散。

在赣州市第五人民医院发布重点监控药品目录之前,江西省、赣州市已经前后发布重点监控药品目录。

▍市级重点监控药品20个

3月19日,江西赣州市卫健委发布《关于调整2019年第一批重点药品监控目录的通知》(以下简称《通知》)。

《通知》称,将注射用艾司奥美拉唑钠等20个药品纳入《2019年第一批市级重点药品监控目录》。

根据《通知》,按照省卫健委《关于建立重点药品监控制度的通知》和《关于调整2019年第一批省级重点药品监控目录的通知》,根据赣州市医疗机构2018年7月-12月非基本药物采购金额情况(省医药采购平台),决定对市级重点药品监控目录进行动态调整。

▍省级重点监控药品20个

3月15日,江西省卫健委发布了《关于调整2019年第一批省级重点药品监控目录的通知》(赣卫办医字〔2019〕10号)(以下简称《通知》)。

《通知》要求,各地各单位要在本文件公布后15个工作日内,在单位官网主动公开本地区、本单位重点药品监控目录。

各医疗机构要在完善落实重点药品处方点评相关奖惩制度基础上,强化信息公开,每月定期在医院OA系统和院务公开栏,对使用药量大、使用金额高和用药不适宜率排名前10%的科室和医生进行公示。

附:赣州市第五人民医院2019年第一批重点监控药品目录

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949096, encodeId=7efb19490967c, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Sep 15 22:01:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363972, encodeId=769e3639e25d, content=好好依好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Apr 02 06:03:31 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363907, encodeId=515e36390e61, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Mon Apr 01 08:30:25 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363891, encodeId=be2236389142, content=应该监控防止滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf2f2432532, createdName=123bc38bm68暂无昵称, createdTime=Mon Apr 01 06:13:32 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363887, encodeId=603d36388ea4, content=加强药品监控,防止过度使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Apr 01 02:12:22 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949096, encodeId=7efb19490967c, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Sep 15 22:01:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363972, encodeId=769e3639e25d, content=好好依好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Apr 02 06:03:31 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363907, encodeId=515e36390e61, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Mon Apr 01 08:30:25 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363891, encodeId=be2236389142, content=应该监控防止滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf2f2432532, createdName=123bc38bm68暂无昵称, createdTime=Mon Apr 01 06:13:32 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363887, encodeId=603d36388ea4, content=加强药品监控,防止过度使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Apr 01 02:12:22 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-04-02 yjs木玉

    好好依好好好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1949096, encodeId=7efb19490967c, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Sep 15 22:01:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363972, encodeId=769e3639e25d, content=好好依好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Apr 02 06:03:31 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363907, encodeId=515e36390e61, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Mon Apr 01 08:30:25 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363891, encodeId=be2236389142, content=应该监控防止滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf2f2432532, createdName=123bc38bm68暂无昵称, createdTime=Mon Apr 01 06:13:32 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363887, encodeId=603d36388ea4, content=加强药品监控,防止过度使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Apr 01 02:12:22 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-04-01 12543c13m83暂无昵称

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1949096, encodeId=7efb19490967c, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Sep 15 22:01:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363972, encodeId=769e3639e25d, content=好好依好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Apr 02 06:03:31 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363907, encodeId=515e36390e61, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Mon Apr 01 08:30:25 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363891, encodeId=be2236389142, content=应该监控防止滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf2f2432532, createdName=123bc38bm68暂无昵称, createdTime=Mon Apr 01 06:13:32 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363887, encodeId=603d36388ea4, content=加强药品监控,防止过度使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Apr 01 02:12:22 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-04-01 123bc38bm68暂无昵称

    应该监控防止滥用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1949096, encodeId=7efb19490967c, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Sep 15 22:01:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363972, encodeId=769e3639e25d, content=好好依好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Apr 02 06:03:31 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363907, encodeId=515e36390e61, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Mon Apr 01 08:30:25 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363891, encodeId=be2236389142, content=应该监控防止滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf2f2432532, createdName=123bc38bm68暂无昵称, createdTime=Mon Apr 01 06:13:32 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363887, encodeId=603d36388ea4, content=加强药品监控,防止过度使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Apr 01 02:12:22 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-04-01 yangchou

    加强药品监控,防止过度使用

    0

相关资讯

400多药品被重点监控

距离2018年仅剩27天——在过去的2017年,据不完全统计,截至11月21日,共计399个药品被重点监控。

100药品被监控、限用!阿托伐、瑞舒伐、消渴丸...

日前,安徽淮南市敲定了2018年重点药品监控目录。有60个品种,被认定为对某种疾病非治疗必需、临床疗效证据不充分、未获得权威疾病诊疗指南推荐或未纳入临床路径表单、不具备药物经济学优势,且用量大或采购金额高。

11省「围剿」医院畅销药

刚刚,广东省重点药品监控制度出台。目前, 已有11省发通知,将6类药困在“华容道”。半个中国都在围剿“神药”,先从广东开始看。

广东重点监控医院前6个月使用金额排前30的药品

今天,广东卫计委发布《广东省卫生计生委办公室关于建立全省医疗机构重点药品监控制度的通知》。

Baidu
map
Baidu
map
Baidu
map